These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 25874347)

  • 1. The humanistic and economic burden of juvenile idiopathic arthritis in the era of biologic medication.
    Gidman W; Meacock R; Symmons D
    Curr Rheumatol Rep; 2015 May; 17(5):31. PubMed ID: 25874347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
    McMahan R; Balfe LM; Greene L
    J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parents' willingness to pay for biologic treatments in juvenile idiopathic arthritis.
    Burnett HF; Ungar WJ; Regier DA; Feldman BM; Miller FA
    Value Health; 2014 Dec; 17(8):830-7. PubMed ID: 25498778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The burden of systemic juvenile idiopathic arthritis for patients and caregivers: an international survey and retrospective chart review.
    Shenoi S; Horneff G; Cidon M; Ramanan AV; Kimura Y; Quartier P; Foeldvari I; Zeft A; Lomax KG; Gregson J; Abma T; Campbell-Hill S; Weiss J; Patel D; Marinsek N; Wulffraat N
    Clin Exp Rheumatol; 2018; 36(5):920-928. PubMed ID: 29600940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Guidelines on biologic drugs for the treatment of children with juvenile idiopathic arthritis (JIA)].
    Bukovac LT; Vidović M; Lamot L; Perica M; Harjacek M;
    Reumatizam; 2013; 60(1):57-66. PubMed ID: 24003687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis.
    Hügle B; Horneff G
    Expert Opin Pharmacother; 2016; 17(5):703-14. PubMed ID: 26678914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Outcomes in Juvenile Idiopathic Arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort.
    Glerup M; Rypdal V; Arnstad ED; Ekelund M; Peltoniemi S; Aalto K; Rygg M; Toftedal P; Nielsen S; Fasth A; Berntson L; Nordal E; Herlin T;
    Arthritis Care Res (Hoboken); 2020 Apr; 72(4):507-516. PubMed ID: 30762291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature.
    Halyabar O; Mehta J; Ringold S; Rumsey DG; Horton DB
    Paediatr Drugs; 2019 Dec; 21(6):469-492. PubMed ID: 31673960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review.
    Ungar WJ; Costa V; Burnett HF; Feldman BM; Laxer RM
    Semin Arthritis Rheum; 2013 Jun; 42(6):597-618. PubMed ID: 23337074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Juvenile idiopathic arthritis in the biologic era: predictors of the disease progression and need for early introduction of biologic treatment.
    Nalbanti P; Kanakoudi-Tsakalidou F; Trachana M; Pratsidou-Gertsi P; Farmaki E; Bamidis P; Papachristou F
    Rheumatol Int; 2018 Jul; 38(7):1241-1250. PubMed ID: 29845429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of patients with juvenile idiopathic arthritis (JIA) in a population-based cohort.
    Zamora-Legoff JA; Krause ML; Crowson CS; Muskardin TW; Mason T; Matteson EL
    Clin Rheumatol; 2016 Jun; 35(6):1493-9. PubMed ID: 26825065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economic burden of juvenile idiopathic arthritis-results from the German paediatric rheumatologic database.
    Minden K; Niewerth M; Listing J; Möbius D; Thon A; Ganser G; Ermisch-Omran B; Zink A
    Clin Exp Rheumatol; 2009; 27(5):863-9. PubMed ID: 19917175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease activity of idiopathic juvenile arthritis continues through adolescence despite the use of biologic therapies.
    Vidqvist KL; Malin M; Varjolahti-Lehtinen T; Korpela MM
    Rheumatology (Oxford); 2013 Nov; 52(11):1999-2003. PubMed ID: 23893666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologics in juvenile idiopathic arthritis: a narrative review.
    Vanoni F; Minoia F; Malattia C
    Eur J Pediatr; 2017 Sep; 176(9):1147-1153. PubMed ID: 28725955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis.
    Salonen PH; Salonen JH; Säilä H; Helminen M; Linna M; Kauppi MJ
    Clin Rheumatol; 2020 Mar; 39(3):853-860. PubMed ID: 31732822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome Monitoring and Clinical Decision Support in Polyarticular Juvenile Idiopathic Arthritis.
    Buckley L; Ware E; Kreher G; Wiater L; Mehta J; Burnham JM
    J Rheumatol; 2020 Feb; 47(2):273-281. PubMed ID: 31308202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective study on 158 Thai patients with juvenile idiopathic arthritis followed in a single center over a 15-year period.
    Vilaiyuk S; Soponkanaporn S; Jaovisidha S; Benjaponpitak S; Manuyakorn W
    Int J Rheum Dis; 2016 Dec; 19(12):1342-1350. PubMed ID: 26176300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis.
    Huang B; Qiu T; Chen C; Zhang Y; Seid M; Lovell D; Brunner HI; Morgan EM;
    RMD Open; 2020 Jan; 6(1):. PubMed ID: 32396520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost of biologics in the treatment of juvenile idiopathic arthritis: a factor not to be overlooked.
    Prince FH; van Suijlekom-Smit LW
    Paediatr Drugs; 2013 Aug; 15(4):271-80. PubMed ID: 23606042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.